BTBP(SH:600161)2023-10-25 16:00Financial Performance - The company's operating revenue for Q3 2023 reached CNY 1,331,040,672.40, representing a year-on-year increase of 30.23%[3] - Net profit attributable to shareholders for Q3 2023 was CNY 320,600,799.11, up 48.49% compared to the same period last year[3] - Basic earnings per share for Q3 2023 were CNY 0.19, a 48.49% increase year-on-year[3] - The diluted earnings per share also stood at CNY 0.19, reflecting the same growth rate of 48.49% compared to the previous year[3] - The company reported a significant increase in net profit attributable to shareholders after deducting non-recurring gains, which rose by 53.60% in Q3 2023[7] - Net profit for the first three quarters of 2023 was CNY 1,207,616,323.66, up 46.2% from CNY 825,898,699.96 year-on-year[15] - The total operating profit for Q3 2023 was -36,530,744.50 RMB, compared to -30,032,164.13 RMB in Q3 2022, indicating a decline of approximately 21.7%[27] - The company reported a total comprehensive income of -35,892,851.40 RMB for Q3 2023, compared to -30,047,917.55 RMB in Q3 2022, reflecting a decline of approximately 19.3%[28] Cash Flow - The net cash flow from operating activities for Q3 2023 surged to CNY 1,069,253,857.72, an increase of 471.18% year-on-year[3] - Cash flow from operating activities for the first three quarters of 2023 was CNY 4,974,086,029.35, significantly higher than CNY 2,994,120,449.21 in the same period of 2022[19] - The net cash flow from operating activities for Q3 2023 was CNY 2,341,139,295.54, a significant increase from CNY 952,360,053.85 in Q3 2022, representing a year-over-year growth of approximately 146%[20] - The net cash flow from financing activities was negative at CNY -286,927,962.83, worsening from CNY -224,534,230.52 in Q3 2022[21] - The company reported a net increase in cash and cash equivalents of CNY 1,154,179,204.70 for Q3 2023, compared to a decrease of CNY -614,192,649.78 in Q3 2022[21] - The cash flow from financing activities in Q3 2023 was 1,451,506,095.86 RMB, significantly higher than 253,407,116.59 RMB in Q3 2022, reflecting a growth of approximately 471.5%[30] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to CNY 14,596,788,026.70, reflecting a 12.80% increase from the end of the previous year[4] - Total liabilities as of the end of Q3 2023 amounted to CNY 2,117,371,560.17, an increase from CNY 1,584,369,943.88 at the end of Q3 2022[13] - Total equity attributable to shareholders reached CNY 9,600,750,278.56, compared to CNY 8,795,740,348.20 in the previous year[13] - The total assets as of September 30, 2023, amounted to CNY 7,547,882,024.14, an increase from CNY 6,097,398,088.57 at the end of 2022[24] - The total liabilities as of September 30, 2023, were CNY 2,356,649,399.82, compared to CNY 787,882,135.95 at the end of 2022, indicating a significant increase[25] Shareholder Information - The company has a total of 52,870 common shareholders as of the reporting date[10] - The largest shareholder, China Biotechnology Co., Ltd., holds 45.64% of the shares, totaling 752,083,740 shares[10] - The company has no pledged, marked, or frozen shares among the top shareholders[10] Operational Insights - The report indicates no significant changes in the company's operational strategies or new product developments during the quarter[11] - Research and development expenses for the first three quarters of 2023 were CNY 58,350,420.20, down from CNY 81,123,931.51 in the same period of 2022[14] - The total cost of operations for the first three quarters of 2023 was CNY 2,618,355,943.43, an increase from CNY 1,992,229,904.77 in the previous year[14] - Management expenses increased to CNY 67,961,600.88 in 2023 from CNY 62,844,993.75 in 2022, marking an increase of about 15%[26]